作为世界博彩公司十大排名癌症患者，您将有独特的机会参与大约100项临床研究试验中的一项或多项，这些试验涉及许多癌症类型的新疗法.

作为世界博彩公司十大排名的病人你可能有独特的机会参加心房纤颤的临床研究试验, 充血性心力衰竭, lipid disorders, 心脏病发作和更多的心脏病状态.

作为世界博彩公司十大排名的病人你可能有机会参加腹腔疾病的临床研究试验, Crohn’s disease, ulcerative colitis, reflux disease, 肝炎和许多其他肠胃疾病.

临床试验研究预防、检测和治疗疾病的新方法. 如果你参与研究，你将帮助推进新的研究性医学疗法. 

Title: 农村和城市接受重大外科肿瘤手术的癌症患者虚弱的描述性和比较分析
Department: Oncology
Diagnosis: Oncology - General
Sub-Investigator(s):
Sponsors: Internal
详细信息(标识符#): NCT05694338
Title: A Randomized, Open-label, 辅助性Sacituzumab Govitecan和Pembrolizumab与内科治疗的3期研究&三阴性乳腺癌术后残留侵袭性病变的apos选择及新辅助治疗
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Gilead Sciences
详细信息(标识符#): NCT05633654
Title: A011801: COMPASSHER2试验(综合使用病理反应评估优化her2阳性乳腺癌的治疗):COMPASSHER2残留病(RD), A Double-Blinded, T-DM1和安慰剂与T-DM1和图卡替尼比较的III期随机试验
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
详细信息(标识符#): NCT04457596
Title: A021806, 可切除胰腺癌围手术期与辅助化疗的iii期试验
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: NCI
详细信息(标识符#): NCT04340141
Title: A031704: PD-Inhibitor (Nivolumab)与Ipilimumab联合，随后是Nivolumab与Ipilimumab. VEGF TKI卡博赞替尼联合纳武单抗:转移性未治疗肾细胞癌的III期试验
Department: Oncology
Diagnosis: Genito-urinary - Renal
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
详细信息(标识符#): NCT03793166
Title: A151216 ALCHEMIST，辅助肺癌富集标记物鉴定和测序试验
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
详细信息(标识符#): NCT02194738
Title: A221805:度洛西汀预防II-III期结直肠癌患者奥沙利铂诱导的周围神经病变
Department: Oncology
Diagnosis: 胃肠道-结肠-直肠
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ALLIANCE
详细信息(标识符#): NCT04137107
Title: CAMBRIA-1: A Phase III, Open-Label, 评估Camizestrant (AZD9833)延长治疗的有效性和安全性的随机研究, a Next Generation, 口服选择性雌激素受体降降剂(口服选择性雌激素受体降降剂)与标准内分泌治疗(芳香酶抑制剂或他莫昔芬)在ER+/HER2-早期乳腺癌和中度或高度复发的患者中进行比较，这些患者已经完成了明确的局部治疗和至少2年的标准辅助内分泌治疗，没有疾病复发
Department: Oncology
Diagnosis: Breast
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: Astra Zeneca
详细信息(标识符#): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, 评估Camizestrant (AZD9833)有效性和安全性的随机研究, a Next-Generation, 口服选择性雌激素受体降降剂(口服选择性雌激素受体降降剂)与标准内分泌治疗(芳香化酶抑制剂或他莫昔芬)作为ER+/HER2-早期乳腺癌和中高或高风险复发患者的辅助治疗，完成了明确的局部区域治疗，没有疾病证据
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator: Joyson Poulose, MD
Sponsors: Astra Zeneca
详细信息(标识符#): NCT04964934
Title: EA5181:随机III期试验MEDI4736 (Durvalumab)作为并发和巩固治疗或单独巩固治疗不可切除的3期NSCLC
Department: Oncology
Diagnosis: Lung- Non-Small Cell
Principal Investigator: Joyson Poulose, MD
Sub-Investigator(s):
Sponsors: ECOG-ACRIN
详细信息(标识符#): NCT04092283
Showing 1-10 of 27 Results